IS6072A - Æðasamloðunar sameindir og mótun á starfsemi þeirra - Google Patents

Æðasamloðunar sameindir og mótun á starfsemi þeirra

Info

Publication number
IS6072A
IS6072A IS6072A IS6072A IS6072A IS 6072 A IS6072 A IS 6072A IS 6072 A IS6072 A IS 6072A IS 6072 A IS6072 A IS 6072A IS 6072 A IS6072 A IS 6072A
Authority
IS
Iceland
Prior art keywords
molecules
activities
formation
cram
vascular clotting
Prior art date
Application number
IS6072A
Other languages
English (en)
Other versions
IS2819B (is
Inventor
Albert Imhof Beat
Aurrand-Lions Michel
Original Assignee
Laboratoires Serono S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono S.A. filed Critical Laboratoires Serono S.A.
Publication of IS6072A publication Critical patent/IS6072A/is
Publication of IS2819B publication Critical patent/IS2819B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
IS6072A 1999-03-11 2001-09-10 Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra IS2819B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (2)

Publication Number Publication Date
IS6072A true IS6072A (is) 2001-09-10
IS2819B IS2819B (is) 2012-12-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6072A IS2819B (is) 1999-03-11 2001-09-10 Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra

Country Status (22)

Country Link
US (3) US7393651B2 (is)
EP (2) EP2292761A1 (is)
JP (2) JP4836329B2 (is)
CN (2) CN100469878C (is)
AT (1) ATE500328T1 (is)
AU (1) AU782139B2 (is)
BR (1) BR0008915A (is)
CA (1) CA2362896C (is)
CZ (1) CZ303128B6 (is)
DE (1) DE60045681D1 (is)
EE (1) EE05497B1 (is)
ES (1) ES2361905T3 (is)
HU (1) HU229376B1 (is)
IL (1) IL145310A0 (is)
IS (1) IS2819B (is)
MX (1) MXPA01009110A (is)
NO (1) NO333085B1 (is)
NZ (1) NZ514091A (is)
PL (1) PL207994B1 (is)
RU (1) RU2244748C2 (is)
WO (1) WO2000053749A2 (is)
ZA (1) ZA200107283B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
ATE500328T1 (de) * 1999-03-11 2011-03-15 Merck Serono Sa Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
JP2010504955A (ja) 2006-09-28 2010-02-18 メルク セローノ ソシエテ アノニム 接合部接着分子ｃ（ｊａｍ−ｃ）結合化合物とその利用方法
PL2907827T3 (pl) 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CN101796188B (zh) * 2007-08-06 2014-10-29 诺松制药股份公司 Sdf-1结合核酸及其用途
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000036102A2 (en) * 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
EP0973892A2 (en) * 1997-03-14 2000-01-26 Human Genome Sciences, Inc. 28 human secreted proteins
EP0970111A2 (en) * 1997-03-21 2000-01-12 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
DE69837761T2 (de) 1997-08-01 2008-01-17 Serono Genetics Institute S.A. 5' ests für sekretierte proteine aus gehirngeweben
US20030082541A1 (en) * 1997-09-17 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (en) * 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
ATE500328T1 (de) * 1999-03-11 2011-03-15 Merck Serono Sa Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer

Also Published As

Publication number Publication date
JP4836329B2 (ja) 2011-12-14
EE05497B1 (et) 2011-12-15
HU229376B1 (en) 2013-11-28
MXPA01009110A (es) 2002-08-20
IS2819B (is) 2012-12-15
JP2010233572A (ja) 2010-10-21
ES2361905T3 (es) 2011-06-24
EP1163337A2 (en) 2001-12-19
US20100267649A1 (en) 2010-10-21
NZ514091A (en) 2004-01-30
ATE500328T1 (de) 2011-03-15
CA2362896A1 (en) 2000-09-14
US8143056B2 (en) 2012-03-27
EE200100472A (et) 2002-12-16
PL350417A1 (en) 2002-12-16
WO2000053749A2 (en) 2000-09-14
HUP0200606A2 (en) 2002-06-29
DE60045681D1 (de) 2011-04-14
CZ20013267A3 (cs) 2002-02-13
NO20014417L (no) 2001-11-12
US20050266426A1 (en) 2005-12-01
RU2244748C2 (ru) 2005-01-20
AU782139B2 (en) 2005-07-07
JP2002537837A (ja) 2002-11-12
US7393651B2 (en) 2008-07-01
CZ303128B6 (cs) 2012-04-18
NO20014417D0 (no) 2001-09-11
EP2292761A1 (en) 2011-03-09
ZA200107283B (en) 2002-12-24
HUP0200606A3 (en) 2004-11-29
CN1355843A (zh) 2002-06-26
CN1637019A (zh) 2005-07-13
IL145310A0 (en) 2003-01-12
PL207994B1 (pl) 2011-02-28
EP1163337B1 (en) 2011-03-02
CN100469878C (zh) 2009-03-18
AU4105100A (en) 2000-09-28
US20080274970A1 (en) 2008-11-06
WO2000053749A3 (en) 2000-12-14
HK1044169A1 (en) 2002-10-11
US7670826B2 (en) 2010-03-02
NO333085B1 (no) 2013-02-25
CA2362896C (en) 2012-07-31
BR0008915A (pt) 2002-04-09

Similar Documents

Publication Publication Date Title
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
DE69132352D1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
DK0771216T3 (da) Fremgangsmåder og præparater til specifik koagulering af tumorvaskulatur
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
DE69535133D1 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
DE69021000D1 (de) Radiomarkierte Peptide mit Antikoagulanswirkung.
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
DE3855449D1 (de) DNS-Klone von menschlichem Thrombomodulin
BR9007115A (pt) Novo trombolitico
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
DK1012286T3 (da) Allelvariant af humant STAT3
EP0832109A4 (en) FACTOR-2, HOMOLOGY OF THE FIBROBLASTS GROWTH FACTOR AND METHOD FOR ITS APPLICATION
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
ATE262307T1 (de) Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
ES2080657A1 (es) Proteasas modificadas.
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.
WO2001068693A8 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide